NCT06814444 Study of the Immunological Infiltrate and Immunometabolic Immunometabolic Profile of Patients with Acute Leukaemia
| NCT ID | NCT06814444 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
| Condition | Acute Leukemia |
| Study Type | OBSERVATIONAL |
| Enrollment | 170 participants |
| Start Date | 2023-11-11 |
| Primary Completion | 2029-12-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 170 participants in total. It began in 2023-11-11 with a primary completion date of 2029-12-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
LThe main aim of this project is to provide an immunophenotypic and immunometabolic characterisation of patients with Acute Leukaemia, before and after therapy, and to understand how changes in the immune system impact the response to therapy. Specifically: 1. The association between the molecular and metabolic characteristics of leukaemic cells and those of the surrounding immune system will be assessed, in order to identify immune-modulatory metabolic mechanisms activated by malignant cells. 2. The association between immunometabolic signatures and response to therapies will be assessed. 3. The role of EVs as a vehicle for metabolic units capable of regulating the metabolism of immune system cells will be explored.
Eligibility Criteria
Inclusion Criteria: PATIENT * Diagnosis of Acute Leukaemia. * Eligibility for a treatment scheme involving either conventional chemotherapy or innovative therapies, such as monoclonal antibodies, molecular therapies with specific targets, metabolic and immunological therapies. * age ≥ 18 years. * Signature of informed consent by patients at the time of diagnosis. Healthy donors (AIL BOLOGNA ODV volunteers) * age ≥ 18 years. * Signature of informed consent. Exclusion Criteria: * no one
Contact & Investigator
Antonio Curti, MD
PRINCIPAL INVESTIGATOR
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Frequently Asked Questions
Who can join the NCT06814444 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Leukemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06814444 currently recruiting?
Yes, NCT06814444 is actively recruiting participants. Contact the research team at antonio.curti2@unibo.it for enrollment information.
Where is the NCT06814444 trial being conducted?
This trial is being conducted at Bologna, Italy.
Who is sponsoring the NCT06814444 clinical trial?
NCT06814444 is sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. The principal investigator is Antonio Curti, MD at IRCCS Azienda Ospedaliero-Universitaria di Bologna. The trial plans to enroll 170 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.